Lantern Pharma Inc. (LTRN)
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
Address
1920 MCKINNEY AVENUE
DALLAS, TX 75201
Founded
2013
Number of Employees
21
Website
http://www.lanternpharma.com
Buyback
| Buyback Data | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $ Amount Purchased ($ in 000s) |
- | - | - | - | - | - | - | $937 | $2,426 | - | - | $1,681 |
| Average Price | - | - | - | - | - | - | - | $7.71 | $6.86 | - | - | $7.08 |
| # Shares Purchased | - | - | - | - | - | - | - | 121,490 | 353,667 | - | - | 237,579 |
| Buyback Performance | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | Average |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Return to Date | - | - | - | - | - | - | - | -48.1% | -41.7% | - | - | -43.5% |
| S&P 500 Return to Date | - | - | - | - | - | - | - | 31.7% | 37.3% | - | - | 34.5% |
| Excess Total Return | - | - | - | - | - | - | - | -79.8% | -78.9% | - | - | -77.9% |
| Quartile Rank |
|
|
|
|
|
|
|
|
|
|
|
|
| Percentile Rank | - | - | - | - | - | - | - | 15% | 15% | - | - | 17% |
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)
Never miss an email alert when insiders at LTRN make a trade.
Creating a free account takes less than one minute